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Objectives. This study assessed the feasibility of an efficacy trial 
comparing angiotensin-converting enzyme inhibition and angio- 
tensin H receptor antagonism in heart failure. Patients with 
moderate or severe heart failure whose condition had previously 
been stabilized by treatment with a converting enzyme inhibitor 
were randomly assigned to receive nalapril or Iosartan. The study 
was designed to detect any signs of clinical deterioration during 
double-blind treatment. 
Background. Losartan is a specific, nonpeptide angiotensin II
receptor-1 antagonist with a vasodilator hemodynamic profile 
similar to that of converting enzyme inhibitors. Although therapy 
with specific receptor blockade has certain theoretic advantages 
over nonspecific onverting enzyme inhibition, demonstration of a 
comparable therapeutic effect in patients with congestive heart 
failure will require a major effort comparing two active agents. 
Methods. One hundred sixty.six patients with stable heart 
failure in New York Heart Association functional class HI or IV 
and an ejection fraction <35% were included in a multicenter, 
double-blind, parallel, enalapril-controlled trial. After a 3-week 
stabilization period with optimal therapy, including digitalis, 
diuretic drags and a conv~,'~ing enzyme inhibitor, patients were 
randomly assigned to 8 weeks of therapy with losartan, 25 mg/day 
(n = 52); Iosartan, $0 mg/day (n = 56); or enalapril, 20 mg/day 
(n -- 58). Patients were assessed with frequent clinical and 
laboratory evaluation and exercise testing. 
Results. No significant differences between groups in terms of 
changes in exercise capacity (6-min walk test), clinical status 
(dyspnea-fatigue index), neurohumoral activation (norepineph- 
rine, N-terminal atrial natriuretic factor), laboratory evaluation 
or incidence of adverse experience were observed. 
Conclusions. The results suggest hat Iosartan and enalapril 
are of comparable efficacy and tolerability in the short-term 
treatment of moderate or severe congestive heart failure. A trial 
designed to compare the ¢9~cacT, tolerabiUty and effect on mor- 
tality of long-term angiotensin II receptqr blockade with convert- 
ing enzyme inhibition is both feasible and ethically responsible. 
(J Am Coil Cardiol 1995;26:43°~ -45) 
The baroreceptor component ofthe juxtaglomerular apparatus 
and the macula densa re activated in congestive heart failure. 
The resultant renin release and angiotensin II production 
causes vasoconstriction along with salt and water retention, 
aggravating the underlying pathophysiology of volume over- 
load and elevated peripheral vascular esistance typically 
present in these patients (1). 
Converting enzyme inhibition reduces peripheral vascular 
resistance and has been shown to be effective in the manage- 
ment of symptomatic congestive heart failure (2). This favor- 
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able clinical response has also been observed by an alternative 
method of inhibiting the renin-angiotensin-aldosterone system 
with the angiotensin II antagonist losartan (3,4). Losartan, the 
potassium salt of 2-butyl-4-chloro-l-[[2'-(1H-tetrazol-5-yl) 
[1,1'-biphenyl]-4-yl]methyl]-lH-imidazole-5-methanol, is a po- 
tent, orally active, specific, competitive nonpeptide angiotensin 
II receptor-1 antagonist of this drug group with no agonist 
properties (5-7). A major active metabolite (EXP3174) with a 
high potency and long duration of action is largely responsible 
for the pharmacodynamic profile of losartan (8). 
Specific receptor antagonism has obvious theoretic advan- 
tages. Angiotensin-converting enzyme cleaves not only angio- 
tensin I to form angiotensin II, but also cleaves bradykinin, 
encephalin and substance P (9). Some important side effects of 
converting enzyme blockade (cough and angioedema) re 
most likely due to these nonspecific actions (10). In addition, 
some nonconverting enzyme-dependent conversion from an- 
giotensin I to angiotensin II occurs locally within cardiac and 
arterial wall tissues (I1). Converting enzyme inhibitor therapy 
appears to enhance this pathway and, thus, the blockade of the 
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potentially detrimental effects of angiotensin II by converting 
enzyme inhibition may remain incomplete. Blocking the ac- 
tions of angiotensin II at the receptor level represents an 
attractive alternative approach to treatment. 
Although a favorable vasodilator and neurohumoral re- 
sponse in patients with congestive heart failure has been 
documented for losartan (3,4), it is dearly imperative to 
demonstrate hat its clinical efficacy, tolerability and effect on 
mortality are comparable tothose demonstrated for converting 
enzyme inhibition (12-14). Such a mortality trial, necessarily 
comparing two active therapies, would be a major effort due to 
the sample size required to detect any diffe-ence in efficacy. 
There are also important ethical considerations now that 
converting enzyme inhibitor therapy has been established as 
essential conventional therapy in patients with heart failure 
(15). 
The objective of this study ~as to assess the feasibility of 
performing such a trial. The study was designed to assess 
exercise eapaeity, clinical and neurohumoral status and to 
detect any signs of clinical deterioration after randomization 
from a converting enzyme inhibitor to losartan. 
Methods 
Study design. This was a multicenter, double-blind, ran- 
domized, parallel, enalapril-controlled trial in patients with 
symptomatic heart failure. Per protocol, all patients had been 
treated optimally for a m,_'nimum of 3 weeks and were given 
placebo tablets (single-blind) during the 3-week stabilization 
period while continuing to receive a converting enzyme inhib- 
itor. Patients were randomly assigned in a 1:1:1 ratio to 8 weeks 
of double-blind therapy with losartan, 25 rag/day; losartan, 
50 mg/day; or enalapril, 20 rag/day. The doses of diuretic and 
converting enzyme inhibitor, as well as the doses of any 
concomitant digitalis or other vasodilator, could not be 
changed for a minimum of 3 weeks before randomization to 
double-blind therapy. The doses of a diuretic and digitalis were 
kept as stable as possible throughout the double-blind period. 
Losartan was initiated at a dose of 12.5 mg, which was 
titrated as tolerated to 25 or 50 nag once daily. Enalapril was 
initiated at a dose of 2.5 rag, which was titrated sequentially to 
5 and 10 mg twice daily. Placebo tablets were provided in 
addition to secure blinding to treatment because of the differ- 
ent dosage intervals of the drugs. Titration occurred at 3- to 
7-day intervals unless it was prevented by symptoms such as 
symptomatic orthostatic hypotension. 
Study patients. One hundred sixty-six patients (37 women 
and 129 men) with s~mptomatic heart failure and a mean 
age ± SD of 64 -+ 10 years (range 32 to 82) were studied. One 
hundred forty patients were in New York Heart Association 
functional class III and 26 in functional class IV. The mean left 
ventricular ejection fraction was 23 +- 6% (range 7% to 35%). 
The etiology of heart failure was ischemic heart disease in 115 
patients (69%), dilated cardiomyopathy in 42 (25%) and 
valvular heart disease in 6 (4%). The mean duration of heart 
failure was 3.9 +-. 4.1 years. One hundred four patients (63%) 
Table 1. Baseline Characteristics of the Three Patient Groups* 
Losartan, Losartan, Enalaprii, 
25 mg 50 nag 20 mg 
(n = 52) (n = 56) (n = 58) 
Men 73% 75% 84% 
Women 27% 25% 16% 
Age (yr) 65.6 ± 9.6 63.9 ± 10.9 63.5 + 8.5 
Etiology 
lschemic heart disease 77% 68% 64% 
Dilated cardiomyopathy 21% 25% 29% 
Valvular disorder 2% 5% 3% 
Other disease 0% 2% 4% 
Secondary diagnoses 
Previous myocardial infarction 67.3% 58.9% 62.1% 
Valvular disorder 34.6% 28.6% 37.9% 
Hypertension 25.0% 26.8% 17.2% 
Duration of CHF (yr) 4.1 ± 5.8 3.7 .-t. 3.2 3.7 ± 3.2 
NYHA functional status 
Class III 83% 80% 90% 
Class IV 17% 20% 10% 
Relative cardiac volume (ml/m z) 664 ± 159 688 ± 183 690 ± 187 
LV ejection fraction (%) 23.3 ± 5.7 23.6 +_ 7.0 23.1 ± 5.9 
6-rain walk test (m) 378 +- 133 392 ± 111 403 ± 112 
Dyspnea-fatigue index 4.5 -+ 2.2 4.3 ± 1.8 4.8 ± 1.8 
*No statistically significant difference among the three groups. Data are 
presented as mean value +- SD or percent of patients. CHF = congestive heart 
failure; LV = left ventrieular; NYI-IA = New York Heart Association. 
had a prior myocardial infarction and 56 (34%) had a valvular 
disorder as secondary diagnoses. The comparability of baseline 
characteristics for each grorp after randomization is detailed 
in Table 1. 
All patients used some form of concomitant medical ther- 
apy (Table 2). No significant betweeg-group differences with 
regard to concomitant therapy were observed. All patients 
gave written informed consent before entx~¢ into the trial. 
Clinical assessment. Patients underwent clinical assess- 
ment three times during the baseline period after screening 
and at weeks 1, 2, 3, 4, 6 and 8 after randomization. Physical 
examination was performed at each visit. Laboratory screen- 
ing, including routine biochemical nd hematologic studies and 
urinalysis, was performed twice during the baseline period and 
Table 2. Concomitant Therapy in the Three Patient Groups* 
Losartan, Losartan, Enalapril, 
25 nag 50 mg 20 mg 
(n = 52} (n = 56) (n = 58) 
Loop diuretic drugs 96% 93% 95% 
Long-acting nitrates 46% 52% 53% 
Digitalis therapy 58% 73% 59% 
Beta blocker therapy 19% l 1% 7% 
Amiodarone 12% 2% 5% 
Allopurinol 23% 13% 12% 
Aspirin 39% 27% 28% 
Anticoagulant agents 40% 46% 55% 
*No statistically significant diffeL'ence among the three groups. Data are 
presented as percent of patients. 
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four times after andomization. A chest X-ray film with relative 
cardiac volume determination (16) and an electrocardiogram 
were taken at baseline and on completion of the study. Left 
ventricular ejection fraction at rest was determined at baseline 
and at 8 weeks by radionuclide ventriculography, two- 
dimensional echocardiography or contrast angiography. 
The primary efficacy variables included assessment ofsymp- 
toms of heart failure, exercise capacity and neurohumoral 
status. The dyspnea-fatigue index (17) was assessed twice at 
baseline and three times after randomization. The 6-min walk 
test (18) was performed three times at baseline and twice after 
randomization. Neurohumoral status (plasma norepinephrine 
and N-terminal atrial natriuretic factor) was measured twice at 
baseline and twice after randomization. 
The protocol classified a patient as exhibiting worsening 
heart failure if one or more of the following criteria were 
satisfied at any time during the trial: serious adverse xperi- 
ence of worsening heart failure or discerl~,,ati,~n of the trial 
for this reason with a need for open or nonprotocol therapy; 
increase in the dosage of a diuretic drug or vasodilator; 
worsening functional class; worsening of two or more variables 
of the signs and symptoms of heart failure; worsening of the 
dyspnea-fatigue index by >-2 points; decrease of >40% in the 
6-rain walk distance; increase in the radiographic signs of 
pulmonary congestion, or cardiac death. 
Neurohumorai assays. Norepinephrine and N-terminal 
atrial natriuretic factor were sampled by direct venipuncture 
from an antecubital vein with patients supine at rest for 
>-20 rain. Plasma norepinephrine was collected into chilled 
tubes containing ethylene glycol tetraacetic acid and gluta- 
thion. Norepinephrine was determined by reverse high pres- 
sure liquid chromatography (19). N-terminal atrial natriuretic 
factor determination was performed with a specific radioim- 
munoassay without prior extraction as described previously (20). 
Statistics. The Fisher exact est was used to compare the 
treatment groups with respect o the distribution of nominal 
demographic characteristics. Analysis of variance (based on 
ranks) was used to compare the treatment groups with respect 
to continuous (ordinal) demographic characteristics, 
Comparisons among the treatment groups with respect o 
continuous end points were based on adjusted means resulting 
from analysis of covariance performed on the change from 
baseline with treatment as a factor, baseline as a covariate and 
investigator as a blocking variable. Within-group changes from 
baseline were analyzed by using the Wilcoxon signed-rank test. 
With regard to the discrete end points, baseline-adjusted 
comparisons between the treatment groups were performed by 
using Cochran-Mantel-Haenszel statistics. The Fisher exact 
test was used to perform between-group comparisons of the 
proportion of patients with worsening heart failure and to 
compare treatment groups with regard to the incidence of 
adverse xperience. With regard to norepinephrine and N- 
terminal atrial natriuretic factor data, differences between 
treatment groups were assessed by using a parametric analysis 
of variance, with the baseline measurement as the covariate. 
All comparisons were made pairwise. 
Table 3. Primary Eficacy Criteria in the Three Patient Groups* 
Losartan, Losartan, Enalapril, 
25 nag 50 mg 20 mg 
(n -- 52) (n = 56) (n = 58) 
Six-rain walk test (m) 
Baseline values 378 ± 134 395 ± 111 397 ± 109 
Change at 8 weeks 18 - 60 12 ± 50 14 ± 48 
Dyspnea-t~atig~e index 
Baseline values 4.5 __. 2.1 4.3 -_. 1.8 4.5 __ 1.8 
Change at 8 weeks 0.7 +_ 2.0I" 0.4 ± 1.7 0.7 ± 1.7~: 
LV ejection fraction (%) 
Baseline values 23.7 ± 6.7 23.7 -+ 6.5 22.7 ± 6.8 
Change at 8 weeks 1.2 +-- 4.2 1.~ ± 5.11" 0.5 __. 6.1 
*No statistically significant difference among the three groups, tStatistically 
significant within-group difference, p < 0.05. :~Statistically significant within- 
group difference, p < 0,001. Data are presented as mean value ± SD. LV = left 
ventricular. 
With 50 patients per treatment group, the study has a power 
of 80% to detect an absolute difference in the incidence of 
worsening heart failure (protocol definition) of 25% between 
two treatment groups, based on an expected enalapril inci- 
dence of 50%, a two-sided test and a 5% significance level. 
Results are presented as mean value _+ standard eviation. A
p value <0.05 was considered statistically significant. No 
formal adjustments due to the multiple end points or multiple 
groups considered were performed. 
Resu l ts  
One hundred fifty-six patients completed the trial per 
protocol. The results of the primary criteria used to assess 
treatment effects are summarized in Tables 3 and 4 and 
displayed in Figure 1. 
Exercise capacity. A major end point was exercise capacity 
as measured by the 6-rain walk test (Fig. la). The average of 
the last two baseline tests was used as the baseline measure- 
ment. The baseline distance (meters) for the losartan 25-mg 
group was 378 +_ 134 with a mean change of 3.7% at 6 weeks 
and 4.5% at 8 weeks. The baseline distance for the losartan 
50-rag group was 395 +_ 111 with a mean change of 4.3% at 6 
weeks and 3,0% at 8 weeks. The baseline distance for the 
enalapril group was 397 _+ 109 with a mean change of 1.5% at 
Table 4. Neurohumoral Variables in the Three Patient Groups 
Losartan, Losartan, Enalapril, 
25 mg 50 mg 20 mg 
(n = 49) (.n = 53) (n = 51) 
N-terminal ANF (pmol/liter) 
Baseline values 2,176 ± 1,327 2,231 ±1,667 2,002 ±1,237 
Change at 8 weeks 48"-.761 -33---689 -127,,,564 
Norepinephrine ( g/ml) 
Baseline values 0.48 ± 0.24 0.50 ± 0.28 0.46 +_. 0.23 
Change at 8 weeks -0.07 ± 0.23't -0.04 __. 0.22 -0.03 ± 0.19 
*n = 48. tStatistically significant within-group difference, p < 0.05. Data re 
presented asmean value +_. SD, ANF = atrial natriumtic factor. 
JACC Vol. 26, No. 2 DICKSTEIN ET AL. 441 
August 1995:438-45 LOSARTAN IN HEART FAILURE 
.l 
6.0 
5.5 
5.0 
4.5 
4.0 
3.5 
3.0 
! 
3000 
2500 
~, 2000 
1500 
I000 
500 
a 
A - Iosartan 25rag 
II - Iosartan 50mg 
b @ - enalapril 20mg 
I*t ............ t 
¢ 
450 
400 
350 
300 
0,60 
0.55 
0.50 
0.4S 
0.40 
0.35 
0.30 
4 6 8 
Baseline weeks weeks weeks 
Figure 1. Results of clinical and neurohumoral measurements at 
baseline and after randomization at 4, 6 and 8 weeks, a, Exercise 
performance during the 6-rain walk test. b, Dyspnea-fatigue index, c, 
Norepinephrine. d, N-terminal trial natriuretie factor (ANF). No 
significant between-group differences were observed. Values hown 
are mean value +_ SD. 
6 weeks and 0.0% at 8 weeks. No significant differences in 
mean change in distance walked were observed between or 
within the treatment groups at any time during the study. 
The dyspnea-fatigue index profile demonstrated within- 
group improvement a 8 weeks for the losartan 25-rag (p < 
0.05 at 8 weeks) and enalapril (p < 0.001 at 8 weeks) groups 
Table 5. Incidence ofWorsening ofSigns and Symptoms of Heart 
Failure in the Three Patient Groups 
Losartan, Losartan, Ena!april, 
25 nag 50 mg 20 mg 
(n = 52) (n = 56) (n = 58) 
Exertional dyspnea 13.4% 17.8% 10.3% 
Edema 9.8% 12.5% 6.8% 
Pulmona~ tales 7.6% 16.0%* 3,s,% 
Orthopnea 3,8% 12,5% 5.1% 
Nocturnal dyspnea 7,6% 7.1% 3.4% 
Third heart sound 11.5% 3.5% 3.4% 
Worsening NYHA class 1.9% 5.3% 1.7% 
*Sta,istieally significant difference v:rsus enalapfil, 20 rag, p < 0.05. Data are 
presented as percent of patients. NYHA class = New York Heart Association 
functional class. 
(Fig. lb). No significant between-group differences were de- 
tected at any time. 
Neurohumoral measurements. Neurohumoral testing 
demonstrated a significant within-group reduction in plasma 
norepinephrine concentration only for the losartan 25-rag 
group at 8 weeks (-0.07 nmol/liter, p < 0.05) (Fig. 1, c and d). 
No significant between-group differences were observed. No 
significant within- or between-group changes in plasma N- 
terminal atrial natriuretic factor concentration were observed 
over 8 weeks. 
No significant differences in mean change in ejection frac- 
tion were observed among the treatment groups. Only the 
mean change from baseline in the losanan 50-rag roup was 
significant (p = 0.02). 
Clinical status. The clinical status of each patient was 
assessed with regard to dyspnea, paroxysmal nocturnal dys- 
pnea, orthopnea, jugular venous pressure, peripheral edema, 
pulmonary rales, third heart sound and functional class at 
baseline and at weeks 1, 2, 3, 4, 6 and 8. No statistically 
significant differences among treatments were observed in the 
distribution of patients with regard to these variables. Func- 
tional class improved in 50 patients (30%), who were evenly 
distributed among the treatment groups. 
Table 5 shows the incidence of worsening of the signs and 
symptoms of heart failure at any time during the trial. A 
significant difference between the losartan 50-rag and enalapril 
groups was noted for pulmonary rales. Otherwise, no statisti- 
cally significant differences were observed among the treat- 
ment groups in the proportion of patients with at least one 
indication of worsening heart failure. The percent of patients 
satisfying the prospective definition of worsening heart failure 
at any time were 59% for losartan 25 rag; 75% for losartan 
50 mg and 60% for enalapril, 20 mg (p = NS). 
Subgroup analyses based on age, gender, ejection fraction 
and functional class were performed. The effect oi each of 
these factors on distance walked was evaluated by an analysis 
of covariance with treatment, investigator and subgroup as 
factors and baseline distance walked as covariate. No treat- 
ment by subgroup interactions were significant for any of the 
subgroups considered. 
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Table 6. Clinical Measurements in the Three Patient Groups* 
Losartan, Losartan, Enalapril, 
25 mg 50 mg 20 mg 
(n = 52) (n = 56) (n = 58) 
Dyspnea 11.5% 19.6% 6.9% 
Dizziness 9.6% 8.9% 6.9% 
Hypotension 5.8% 7.1% 6.9% 
Cough 3.8% 7.1% 6.9% 
Edema 7.7% 3.6% 3.4% 
Upper respiratory tract infection 7.7% 3.6% 3.4% 
Abdominal pain 1.9% 7.1% 1.7% 
Discontinuedi" 1.9% 3.6% 8.6% 
*No statistically significant difference among the three groups, tStudy 
diseontinuations due to adverse xperience. Data are presented as percent of 
patie,~. 
Safety and tolerance. The safety of losartan was character- 
ized by evaluating the incidence of clinical and laboratory. 
adverse xperience. Adverse xperience l d to discontinuation 
of the trial in one patient in the losartan 25-rag group, two in 
the losartan 50-rag roup and five in the enalapril group (Table 
6). The most common adverse experiences reported were 
dyspnea, worsening of heart failure, hypotension, dizziness and 
cough. Clinical adverse xperience was noted in 36 patients in 
the losartan 25-rag group, 38 patients in the losartan 50-rag 
group and 30 patients in the enalapril group. Two patiems in 
the losartan 50-rag group and two in the enalapril group died. 
No patient discontinued the trial because of a laboratory 
adverse experience. No statistically significant differences 
among treatment groups were observed. 
Six patients in the losartaa 25-rag group, five in the losartan 
50-mg group and eight in the enalapril group had at least one 
laboratory adverse xperience. No patient in any of the three 
treatment groups had a serious laboratory adverse xperience 
necessitating discontinuation, 
Laboratory screening revealed no significant within- or 
between-group differences at8 weeks for serum sodium or uric 
acid. Table 7 displays the results for blood urea nitrogen 
serum creatinine and potassium. Clinically minor but signifi- 
cantly different changes between patients receiving losartan 
(25 or 50 mg) and those receiving enalapril w~re observed at 
week 8. Slight increases in these variables were observed in 
those receiving enalapril and slight decreases inthose receiving 
losartan. 
Discuss ion 
Losartan is a specific, nonpeptide angiotensin II receptor-1 
antagonist with hemodynamic and neurohumoral responses 
comparable tothose seen with converting enzyme inhibition in 
patients with congestive heart failure (3,4). Filling pressures 
are reduced with a modest increase in cardiac output. The 
hormonal response is also similar, with a marked increase in 
plasma renin activity and a moderate reduction in plasma 
aidosterone and norepinephrine. However, in contrast o 
Table 7. Laboratory Results in the Three Patient Groups 
Losartan, Losartan, Enalapril, 
25 mg 50 mg 20 mg 
(n = 48*) (n = 51") (n = 49*) 
Serum creatinine (mg/dl) 
Baseline values 1.23 *- 0.27 1.16 ± 0.34 1,18 + 0,23 
Change at 8 weeks 0.03 ± 0.24 -0.05 ± 0.29t 0.04 *_ 0.13~: 
BUN (rag/all) 
Baseline values 53.3 ± 32.0 50.5 ± 24.0 52.9 +_ 22.6 
Change at 8 weeks -3.4 +_. 26.2t -2.8 ± 1 LOt 5.i ± 17.6:i: 
Serum potassium 
(mmol/liter) 
Baseline values 4.2 ± 0.3 4.1 +_- 0.4 4.2 _ 0.4 
Change at 8 weeks -0.1 ± 0.4~§ -0.1 ± 0.4§ 0.1 ± 0.5;t 
Serum sodium (mEq/liter) 
Baseline values 139.7 _+ 2.6 139.9 ± 3.2 138.8 ± 3.3 
Change at 8 weeks 0.4 ± 2.6 -0.4 -+ 2.7 -0.4 _+ 2.9 
Serum uric acid (mg/dl) 
Baseline values 7.85 ± 2.17 8.41 ± 2.09 7.89 ± 2.16 
Change at 8 weeks 0.35 ± 2.74 -0.30 ± 1.72 0.17 _+ t.14 
*Minimal sample size for each variable, tStatisticai!y significant difference 
versus enalapril, 20 rag, p < 0.05. :[:Statistically significant within-group differ- 
ence, p < 0.05. §Statistically significant difference versus enalapril, 20 rag, p < 
0.001. Data are presented as mean value ± 8D. BUN = blood urea nitrogen. 
results with converting enzyme inhibition, angiotensin II levels 
increase. 
Angiotensin receptor antagonism versus converting enzyme 
inhibition. The tneoretic advantages of specific receptor an- 
tagonism over nonspecific converting enzyme inhibition, such 
as an improved side effect profile and blockade of the poten- 
tially detrimental effects of local, nonconverting enzyme- 
dependent conversion from angiotensin I to angiotensin II, 
deserve further investigation. Similarly, the effects of unop- 
posed stimulation of angiotensin (subtype 2) receptors by 
elevated angiotensiu II levels in response to angiotensin (sub- 
type 1) receptor antagonism also must be explored. 
The degree to which inhibition of bradykinin degradation 
contributes to the favorable hemodynamie r sponse of con- 
vetting enzyme inhibition is still uncertain (3,11). Recent 
hemodynamic studies (21) with renin inhibition suggest hat 
bradykinin does not play a substantial role, in that addition of 
a converting enzyme inhibitor does not produce further vaso- 
dilation. An apparent attenuation ofsome benefit for convert- 
ing enzyme inhibiters with concomitant aspirin therapy, pre- 
sumably due to inhibition of prostaglandin synthesis, has been 
reported (22). However, no data exist indicating whether this 
may also be true for angiotensin II receptor antagonism. There 
is also specu!ation concerning the possible synergistic effects of 
combined converting enzyme inhibition and angiotensin II
receptor antagonism. These issues deserve further attention. 
The future role for angiotensin II antagonists in the man- 
agement of patients with congestive heart failure will ulti- 
mately depend on direct comparison with the clinical etficacy 
of angiotensin-converting e zyme inhibitors. This trial was 
designed to assess the feasibility of a larger efficacy trial by 
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randomizing patients with moderate or severe heart failure, 
whose condition had previousi~ stabilized with converting 
enzyme inhibition, to treatment with losartan or enalapril. 1'Io 
significant differences among roups in terms of changes in the 
primary efficacy variables (i.e., exercise capacity [6-min walk 
test], clinical status [dyspnea-fatigue index] or neurohumoral 
activation [norepinephrine, atrial natriuretic peptide]) were 
observed. Minor differences among the groups reached signif- 
icance with regard to the signs of worsening heart failure 
strictly applied at every visit during the trial) and laboratory 
results. Some spurious ignificance would be expected to occur 
in the analysis of a large data base, especially with multiple 
groups and multiple nd points. 
However, some of these data (effect on blood urea nitrogen, 
creatinine and potassium) may well have a pharmacologic 
basis. Although both angiotensin-eonverting e zyme inhibition 
and angiotensin receptor antagonism will attenuate he selec- 
tive efferent arteriolar vasoconstriction i the glomerulus by 
angiotensin II, only converting enzyme inhibition also inhibits 
the degradation of bradykinin, which causes additional selec- 
tive efferent arteriolar dilation in the giomerulus. This effect 
leads to a more pronounced reduction i  filtration fi'action and 
might well explain the observed ifferences related to renal 
function (23). The clinical significance of these observations i  
uncertain. 
The lack of detected neurohumoral ctivation after ran- 
domization to losartan in this trial is important. Deterioration 
in clinical status is known to result in renin activation (24) 
along with elevated levels of plasma norepinephrine (25) and 
atrial natriuretic peptide (26). The results of this trial 1) 
suggest that losartan and enalapril are of comparable efficacy, 
and 2) indicate that patients with moderate or severe heart 
failure can safely undergo a trial in which they would be 
randomly assigned to continued treatment with a converting 
enzyme inhibitor or new treatment with an angiotensin II
receptor antagonist. 
Compelling evidence from large randomized trials has 
confirmed that converting enzyme inhibition is well tolerated 
by patients with congestive heart failure, and serious adverse 
experience has been uncommon (12,13). However, angioneu- 
rotic edema, symptomatic hypotension and increases inserum 
creatinine and potassium can occasionally create clinical prob- 
lems. It remains to be seen whether angiotensin II inhibitors 
will be less problematic n this regard. Cough is a serious and 
relatively common side effect of converting enzyme inhibition; 
it has an incidence rate as high as 7% to 25% in a large sample 
(27) and limits substantially the proportion of patients eligible 
for therapy. It is thought that cough is secondary to increased 
bronchial reactivity due to reduced egradation ofproinflam- 
matory mediators uch as bradykinin and substance P (28). 
Because angiotensin II inhibitors do not inhibit the degrada- 
tion of the biologically active peptides in the kallikrein-kinin- 
prostaglandin system, it is expected that they wql represent a 
useful alternative therapy for these patients. 
However, demonstration f a comparable therapeutic effect 
with angiotensin II antagonism in patients with congestive 
heart failure poses practical and ethical problems. Converting 
enzyme inhibition reduces peripheral vascular esistance and 
has been shown to be effective in the management of symp- 
t,)matic ongestive heart failure. Improvement i  clinical status 
(29), hemodynamic status (30) and exercise performance (31) 
has been demonstrated, and therapy is associated with a 
reduction in mortality in patients with severe congestive heart 
failure (12). Two large trials (13,14) have provided convincing 
evidence that long-term therapy improves prognosis n patients 
with moderate but symptomatic heart failure. Improved sur- 
vival in patients with a reduced ejection fraction has been 
demonstrated with therapy ivitiated early during the convales- 
cent phase after myoc:r:iial infarction (32). Converting en- 
zyme inhibition therapy is therefore stablished as potent 
intervention with lessening of dyspnea, exercise intolerance 
and mortality in symptomatic patients. Comparable data eval- 
uating the effects of specific angiotensin 1I receptor blockade 
are lacking. 
The issues concerning the design of an equivalence trial are 
complex. Sample size requirements are dependent on the 
outcome of previous trials of the standard treatment. Adjust- 
ments to protect against inadequate sample size are required 
and depend on the definition of equivalence with regard to the 
overall event rate. The statistical considerations hwolved in 
sample size calculation for the design of an e,3uivalence 
mortality trial between a converting enzyme inhibitor and an 
angiotensin II antagonist have recently been reviewed in detail 
(33). 
Study limitations. This study has several noteworthy limi- 
tations. Eighty-nine percent of the patients were previously 
receiving maintenance therapy with a converting enzyme in- 
hibitor. This bias selects patients who tolerate therapy well and 
it reduces the incidence of adverse xperience (especially 
cough and hypotension) that might be expected in previously 
untreated patients. 
The long-term effects of previous converting enzyme inhi- 
bition may have been partially operative for a period after 
randomization to iosartan (34), and an 8-week trial may not be 
adequate to detect deterioration i  clinical status during 
long-term therapy. However, such deterioration was observed 
4 to 6 weeks after cessation of therapy with quinapril (35), as 
was a high incidence of major adverse vents within 3 weeks 
after cessation of enalapril therapy (36). Nevertheless, the 
results of this trial should not be extrapolated to indicate 
comparable fficacy with long-term therapy. We emphasize 
that this pilot trial was not designed to possess adequate power 
to rule out clinically important differences among the groups 
but to assess the feasibility of a larger, definitive trial. 
The optimal dose of losartan in patients with heart failure is 
not sufficiently clarified. This trial evaluated the two dosages 
(25 and 50 rag) that have previously demonstrated the best 
hemodynamic efficacy. However, the expected negative neuro- 
humoral feedback pattern with a dose-related incremental 
angiotensin II response has been reported (3). Unexpectedly, 
higher doses did not appear to exhibit a more pronounced 
vasodilator hemodynamic response. Theoretically, elevated 
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angiotensin II levels could result in a vasoconstriction that 
might attenuate the hemodynamic response (37). Certainly, 
the known heterogeneity of angiotensin II receptors could 
provide a mechanistic explanation in that losartan does not 
block the angiotensin (subtype 2) receptor (38). However, 
previous studies did not have adequate power to rule out 
additional hemodynamic effects with higher doses. Future 
research must address these issues to adequately elucidate the 
role of selective angiotensin II antagonism in the management 
of patients with chronic heart failure. 
Conclusions. The present data indicate that a definitive tri~! 
designed to compare the clinical efficacy, tolerability and effect on 
mortally, of angiotensin II receptor blockade and converting 
enzyme tnhibition is both feasible and ethically responsible. 
The expert technical ssistance of Torbj0rn Aatsland, RN, Hjertelaget Research 
Foundation, is gratefully acknowledged. 
Appendix 
Participating Centers and Investigators 
The following investigators and centers participated in this trial. 
Denmark: Erik Agner, Jlargen Kanters, Hdsing6r Hospital. Stig 
Haunst~, Vibeke S0rensen, Mette Hyllested, Lars Sondergaard, Rigs- 
hospitalet. Hans Ibsen, Jens Rokkedal, Rene Worck, GIostmp Hospital. 
Kristian Thygesen, Anne Seji Kudsen, Aage N0rgaard, ~rhus Amtssy- 
gehas. 
Finland: Matti Huttunen, Savolinna Central Hospital. Juha Mus- 
tonen, Matti Ketonen, Jarkko Nurminen, North-Karelia Central Hos- 
pital. Jouko Remes, Seppo Hietakorpi, Kuopio University Hospital. 
Risto Sipila, Janne Rapo|a, 1orvi Hospital. 
Norway: Kenneth Dickstein, Svein Skeie, Central Hospital in Roga- 
land. John Kjekshus, Ellinor Aaser, Ril~hospitalet. Gerhard "Con der 
Lippe, Eva Gerdts, Reidar Pettersen, Haukeland Hospital. Arne West- 
helm, Anne-Elin Hofstad, Ullevdl Hospital. 
Sweden: Per Ahlstr6m, Uif Rosenqvist, Motalc Hospital. Leif 
Erhardt, Ronnie Willenheimer, Malmi~ General Hospital. Per L6fdahl, 
Hdsingborg Hospital. Olaf Nyquist, Eva Str~[it, G&an ~:e, nnebaek, 
ltuddinge Hospital. Lars Ryden, Clues Hofman-Bang, Karolinska Hos- 
pital. Peter Smedg~rd, Maria Aunes, SkOvde Central Hospital. Finn 
Waagstein, Claes-H'~kan Bergh, Bengt Rundqvist, Bjern Lindel6w, 
Bert Andersson, Sahlgren's Hospital. 
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